Drugs / ECROMEXIMAB
ECROMEXIMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00199342 | Nov 2004 → Oct 2005 | melanoma | Kyowa Kirin, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00679289 | Mar 2008 → Feb 2014 | cutaneous melanoma, metastatic melanoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECROMEXIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109057 ↗ |
| Known as | KM-871 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109057 ↗ |
| Known as | KW-281 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109057 ↗ |
| Known as | KW2871 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00679289 ↗ |
| Modality | Monoclonal antibody | “A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma” NCT00199342 ↗ |
| Route | Intravenous | “ecromeximab administered intravenously once every 2 weeks” PMID 28489678 ↗ Aug 2017 |